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Abstract: Chikungunya virus is an emerging arbovirus that is widespread in tropical regions
and is spreading quickly to temperate climates with recent epidemics in Africa and Asia, and
documented outbreaks in Europe and the Americas. It is having an increasingly major impact on
humankind, with potentially life-threatening and debilitating arthritis. There is no treatment
available, and only in the last 24 months have lead compounds for development as potential
therapeutics been reported. This perspective discusses the chikungunya virus as a significant,
new emerging topic for medicinal chemistry, highlighting the key viral target proteins and their
molecular functions that can be used in drug design, as well as the most important ongoing
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developments for anti-chikungunya virus research. It represents a complete picture of the current
medicinal chemistry of chikungunya, supporting the development of chemotherapeutics through
drug discovery and design targeting this virus.
Key words: alphaviruses; arboviruses; chikungunya virus (CHIKV); chikungunya fever
(CHIKF); non-structural proteins; envelope proteins; drug discovery
I. INTRODUCTION
I.1. Classification, History and Clinical Features. Chikungunya virus (CHIKV) is an
emerging arthrogenic arbovirus that belongs to the alphavirus genus, family Togaviridae. It has
been responsible for major outbreaks of devastating human arthritis disease during the past five
years.1 Chikungunya fever caused by the virus was first described in 1952,2 after an outbreak on
the Makonde Plateau (named after an ethnic group from East Africa), along the border between
Tanganyika and Mozambique. During this period, a high proportion of residents of all ages were
affected by a distinctive disease with a sharp onset of crippling joint pains, severe fever, and a
conspicuous rash.2 The elders of the Makonde tribes could not remember any previous, similar
epidemics with these symptoms, suggesting that this was a new illness. The word
‘‘Chikungunya’’ translates to ‘‘that which bends up’’ relating to the stooped posture developed
as a result of rheumatologic inflammation.3 Subsequently, only minor outbreaks occurred
periodically in Africa, however major epidemics were reported in the 1960s and 70s in India and
Southeast Asia.4 After the 1973 outbreak in India, only sporadic activities were detected for the
next 30 years, with no major recurrence until a large outbreak in Kenya in 2004.5 This initiated a
spreading epidemic that reached numerous islands of the Indian Ocean, India, and parts of
Southeast Asia, and was further detected in 18 countries throughout Asia, Europe, and North
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America via imported infectious carriers. Over the course of five years, an estimated more than
2 million cases occurred, with outbreaks in several countries where the virus had not been
previously documented.6 The first CHIKV hit in Europe occurred in Italy in 2007.7,8
Nearly 40 countries have detected chikungunya virus infected cases thus far (Figure 1).
The US National Institute of Allergy and Infectious Diseases (NIAID) in 2008 listed CHIKV as
a category C priority pathogen: this category includes pathogens that could be engineered for
mass dissemination in the future, or due to their high morbidity and mortality rates and those
with major health impacts.9, 10 Recent epidemics were reported in India (1.4 to 6.5 million cases
in 2006-2007), and 3,000 - 42,000 cases were detected in 2009 in Malaysia and Thailand.11,12
The CHIKV mortality rate has been estimated to be 1:1000 and most of the deaths occur in
neonates, adults with underlying conditions and the elderly.10
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Figure 1. Worldwide distribution of the Chikungunya virus.10 Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Microbiology, (Vol 8), copyright (2010).
CHIKV can be transmitted through an urban cycle, man to mosquito to man, or a
sylvatic cycle, animal to mosquito to man.13 The virus is transmitted to humans by mosquitoes
of the Aedes genus (Aedes furcifer in Africa and Aedes aegypti in Asia), similar to the dengue
fever causing virus. However, the Ae. albopictus mosquito was extensively implicated in
CHIKV transmission during the 2005-2006 outbreak on Reunion island.10
The switch of the CHIKV vector from Ae. aegypti to Ae. albopictus arose from an
insufficient number of Ae. aegypti for its transmission.14 A mutation in the E1 envelope protein,
A226V, increased the CHIKV fitness in Ae. albopictus and improved the transmissibility of the
4

virus through Ae. albopictus to vertebrate species.15 Ae. albopictus has spread to Madagascar,
the Indian Ocean nations, Africa, Southern Europe and the USA.16, 17 Virus transmission has
been also reported as a result of maternal-foetal transmission in recent epidemics.18
Chikungunya fever (CHIKF): The symptoms of CHIKF infection generally start 4–7 days after
the mosquito bite. Infection presents in two phases, the first being acute, while the second stage
is persistent (chronic), causing disabling polyarthritis.19 Acute infection lasts 1–10 days and is
characterized by a painful polyarthralgia, high fever, asthenia (weakness), headache, vomiting,
rash, and myalgia (muscle pain). Rash is the least reliable symptom, presenting in as few as 19%
of patients. When a rash is present, it is typically maculopapular in nature, but recent studies
have also noted vesiculobullous lesions with desquamation.20 The persistent chronic CHIKF
phase is characterized by polyarthralgia (aches in the joints, joint pains) that can last from weeks
to years beyond the acute stage.21 Eighteen months after disease onset, 40% of patients are found
to still have anti-CHIKV immunoglobulin M (IgM).22
CHIKV attacks fibroblasts, explaining the involvement of muscles, joints, and skin
connective tissues. The high number of nerve endings within the joints and muscle tissues
explains the pain associated with CHIKF. Neurological manifestations have also been described
during the most recent epidemics in India, including disorders such as encephalitis, peripheral
neuropathy, myelopathy, myeloneuropathy and myopathy.23 Moreover, some cases with multiorgan failure have also been noted.24 Eye infection (Chikungunya neuroretinitis) has also been
reported where patients suffered from a sudden, painless diminution of vision in both eyes.25,26
CHIKV can also infect the cornea and be transmitted via the ocular route.27
I.2. Virology of the CHIKV. The CHIKV genome (Figure 2) is a positive sense, single
stranded RNA genome of about 11.8 Kb in size. It consists of two open reading frames
(ORFs),28 one in the 5` end encoding the non-structural protein precursors:
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 nsP1: involved in viral mRNA capping via its guanine-7-methyltransferase and
guanylyltransferase enzymatic activities,
 nsP2: acts as protease and helicase,
 nsP3: part of the replicase unit and an accessory protein involved in RNA synthesis,
 nsP4: RNA-dependent-RNA polymerase,
The nsP123 precursor and nsP4 function as part of a complex for viral negative-strand RNA
synthesis. The 3` end ORF encodes the structural proteins, the capsid (C), envelope
glycoproteins E1 and E2 and two small cleavage products (E3, 6K). The untranslated junction
region (J) (Figure 2) contains its internal promoter, a conserved sequence of 21 nucleotides, for
transcription of the sub-genomic mRNA in other alphaviruses (sindbis virus, for more details
see ref 29).29

Figure 2. Schematic representation for The CHIKV genome showing the RNA sequence ORFs.

The CHIKV surface consists of 80 trimeric spikes composed of heterodimers of the envelope
glycoproteins (E1 and E2) in the lipid bilayer. Similar to other members of the alphaviruses, the
6

CHIKV starts its life cycle (Figure 3) by entering the target cells by pH dependent endocytosis
in clathrin coated vesicles via receptor mediated interaction,30 but the exact mechanism by
which it does so remains unclear. CHIKV has been shown to replicate in a large number of cell
types including epithelial, endothelial and fibroblast cells as well as monocyte derived
macrophages.30 A recent study identified prohibitin (PHB) as a microglial cell expressed
CHIKV binding protein.31 PHB is an evolutionarily conserved and ubiquitous protein that
consists of two highly homologous proteins of different molecular weights. PHB1 has a mass of
approximately 30 kDa while PHB2 is approximately 37 kDa. The two proteins oligomerize, and
hetero-oligomerization is essential for protein stability.32 PHB has been shown to be present in
multiple cell compartments including the mitochondria, cytoplasm and nucleus in addition to its
expression on the cell surface.33 PHB1 was confirmed as a CHIKV E2 binding protein, but not
PHB2.31 PHB1 was found to be involved in the internalization process either on its own or as
part of a complex, further suggesting that a PHB-virus interaction may be mediated by the
specific PHB molecule that interacts with the virus. Experimental down-regulation of PHB1
significantly reduced the level of infection in tested cell lines. However, the authors believe that
this mechanism might be only one pathway by which CHIKV can enter the susceptible cells.31
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Figure 3. Schematic representation of the Chikungunya virus life cycle.

After entering the cell, the endosome acidic environment triggers conformational
changes with the viral envelope proteins (E1 and E2 complex) reorganizing, leading to
dissociation of the E2-E1 heterodimers, and formation of E1 homotrimers. E1 trimerizes and
inserts into the target membrane with the hydrophobic fusion peptide (fusion loop) and refolds
to form a hairpin-like structure. Exposure of the E1 fusion peptide mediates virus host cell
membrane fusion, releasing the nucleocapsid into the cytoplasm.34,35 This process depends on
low pH and cholesterol, which is also required for budding during alphavirus infection.36,37

8

Two non-structural proteins precursors are translated from the viral mRNA, and are then cleaved
generating nsP1, 2, 3 and 4. During translation, nsP123 binds to free nsP4 and with some cell
proteins, forming the replication complex,38,39 which synthesizes a full-length negative-strand
RNA intermediate required for replication. When the nsP123 concentration increases, it is
cleaved into nsP1, nsP2, nsP3 and nsP4 which forms, along with host cell proteins, the positive
strand replicase, producing the 26S sub-genomic positive strand RNAs and genomic (49S)
RNAs.39 Promoters present in the negative strand initiate the transcription of 26S sub-genomic
positive stranded RNA which encodes the structural proteins precursors. The latter is cleaved by
a serine protease to yield the capsid (C) which remains in the cytoplasm (Figure 3), pE2, 6K and
E1.40 The C protein might be responsible for such autoproteolytic activity as it has a number of
conserved sequences which have similar activity, and are common in other alphaviruses.41
pE2 and E1 are translated in the endoplasmic reticulum (Figure 3) and processed in the
Golgi, and are then moved to the plasma membrane, where pE2 is cleaved by furin-like protease
activity in the host cell into E2 and E3.42 The assembly of virions begins in the cytoplasm of the
cell, where the formation of the nucleocapsid with 120 dimers of the C protein starts to occur.43
The assembled particle buds at the cell membrane as spherical particles of 65 to 70 nm in
diameter, composed of genomic RNA molecules and the capsid proteins and enveloped in a
host-derived lipid membrane.
I.3. The Development of CHIKV Vaccine. There is an urgent need to control the spreading of
CHIKV, however, there is little understanding of the interaction between the chronic CHIKV
infection and the immune system in defending the body against any subsequent reinfection.10
The immune responses are strongly accepted to induce autoimmunity, by cross reactivity
between viral and host antigens. The B cells and T cells might respond to CHIKV and this may
contribute to the long-term joint disease experienced by many convalescent patients.44
9

Thus far, there is no licensed CHIKV vaccine. Some vaccine preparations that involved
either formalin inactivation or Tween-ether extracts of virus45 showed high immune responses
without any adverse effects. In 2000, the US Army carried out a Phase II clinical trial examining
a live attenuated CHIKV vaccine.46,47,48 The vaccine was formulated from a human MRC-5 cell
line as a lyophilized supernatant. In this study, subjects that received the vaccine developed
neutralizing antibodies, and fewer subjects showed mild to moderate joint pain.48
In 2009, one study reported a vero cell adapted formalin inactivated prototype vaccine
with alhydrogel as adjuvant that was prepared using an Indian CHIKV strain implicated in the
2006 epidemic. The humoral immune response was characterized by high titer antibodies that
have been confirmed through microcytotoxicity assays and in vivo neutralization tests.
Therefore, this could be a promising, safe and effective vaccine eliciting a long lasting
protective immune response.49
A live CHIKV vaccine was developed in 2011 that elicits a protective immune response
with no detectable disease in mice. It is also unable to infect mosquito vectors, which is an
important safety feature for a live virus vaccine that could be used in non endemic areas to
immunize travellers or laboratory personnel. However, this vaccine candidate is still under
evaluation in nonhuman primates.50 Other promising CHIKV vaccine candidates that depend on
virus-like particles are in early stages of preclinical development.51,52 A successful virus-like
particle vaccine based on viral structural proteins was tested on nonhuman primates and was
found to produce neutralizing antibodies that protect against viremia after high-dose challenge.
When these antibodies were transferred into an immunodeficient host (a mice), the host was
protected indicating a passive immunity.53
With the ongoing vaccine development research against the CHIKV, the world remains
under the threat of rapidly spreading CHIKV infections, and this emphasizes the importance of
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developing chemotherapeutics targeting the virus for controlling already existing infections in
devastated areas.
II. EMERGING NOVEL CHIKV TARGETS
As previously mentioned, the CHIKV genome is formed of 2 ORFs, one from the 5` end
coding for nsP1, nsP2, nsP3 and nsP4. The 3` end ORF encodes the the capsid (C), envelope
proteins E1, E2, E3 and 6k (Figure 2). These proteins, which mediate essential steps in the
lifecycle (Figure 3) of the virus,10 could be possible targets for drug design.
II.1. Non-Structural Proteins
II.1.1. Non-structural protein 1. Like in other alphaviruses, CHIKV nsP1 is a palmitoylated
535 amino acid protein. The N-terminal region is a methyltransferase and guanylyltransferase
involved in capping and methylation of the newly formed viral genomic and subgenomic
RNAs.54 In early 2013, it was shown that CHIKV nsP1 acts as antagonist for the bone marrow
stromal antigen 2 (BST-2).55 BST-2 is one of the host cell defence mechanisms, and is induced
by interferon (INFα). BST-2 expression results in retaining viruses at the surface of the infected
cells.56 BST-2 was found to co-localize with CHIKV E1 and nsP1, but only nsP1 is able to
down-regulate BST-2 expression, thereby inhibiting virus tethering on the cell surface.55 This
activity of the CHIKV nsP1 is similar to that of the HIV-1 Vpu protein56 in that both repress
BST-2. This discovery will help in developing BST-2 mediated therapeutics targeting the nsP1.
II.1.2. Non-structural protein 2. The non-structural protein 2 (nsP2) of alphaviruses is a
multifunctional protein.57,58,59,60 The proteolytic domain has been allocated to its C-terminal
section which forms a papain like cysteine protease (also known as thiol protease).57,61 The nsP2
proteolytic activity is critical for virus replication and is responsible for cleavage of the nonstructural polyprotein complex.62,63

11

The proteolytic activity of the CHIKV nsP2 has been demonstrated,64 and the enzymatic
activities within the N-terminus have been recently investigated. It was found to have RNA
triphosphatase activity that performs the first of the viral RNA capping reactions. It was also
found to have a nucleotide triphosphatase (NTPase) activity, fueling the RNA helicase activity
performed by the C-terminal domain.65 CHIKV-nsP2 also has 5`-triphosphatase (RTPase)
activity that removes the γ-phosphate from the 5` end of RNA. Both NTPase and RTPase
activities are completely dependent on Mg2+ ions.65
Both N and C domains are composed of α-helices and β-strands (Figure 4). The N
terminus is dominated by α-helices, whereas the C-terminal domain contains helices and strands.
The central β-sheets are flanked by α-helices. The crystal structure of CHIKV nsP2 protease has
been solved, and is composed of 324 residues. Being a cysteine protease, the catalytic
mechanism involves a nucleophilic cysteine thiol in a catalytic dyad.66 Analysis of the CHIKV
nsP2 crystal structure shows 6 cysteine residues, three in the N-terminus (Cys1013, Cys1057
and Cys1121) and three in the C-terminus (Cys1233, Cys1274 and Cys1290) as shown in Figure
4. Since the proteolytic activity is isolated in the C-terminus,64 one of the three cysteine residues
in the C-domain might contribute as the catalytic thiol.
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Figure 4. CHIKV nsP2 crystal structure showing the N- and C-terminal domains, cysteine
residues shown in yellow balls and stick form (pdb code: 3TRK67, no citation was found for the
crystal structure).

The first step in the mechanism of cysteine proteases catalysis is usually the
deprotonation of a thiol group within the enzyme active site by an adjacent amino acid
containing a basic side chain, often a histidine residue.68 Among the three cysteine residues in
the C-terminus (Figure 5), the Cys1274 residue is less likely to be involved in the catalytic
mechanism as only one His residue (His1314) is nearby, whereas for the other cysteine residues,
four His residues, His1222, His1228, His1229 and His1236 could be associated in the
deprotonation mechanism (Figure 5).
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Figure 5. Schematic representation of the CHIKV nsP2 C-Domain showing the positions of the
cysteine residues (yellow) and histidine residues (green), generated from the crystal structure
pdb file code: 3TRK.

In 2012, Singh Kh et al. reported the development of a homology model of the CHIKV
nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan equine encephalitis
virus (VEEV),69 in order to locate the active site of the protease. The critical residues in nsP2
were identified by docking three different peptides to identify the residues responsible for nonstructural protein cleavage of the nsP1-2, nsP2-3 and nsP3-4 peptides. These three peptide
sequences represent the substrates for the nsP2 proteolytic processing with a remarkable
preference of nsP3-4>nsP1-2>nsP2-3.70
The active site was investigated and was found to lie in the C-terminal domain69 (Figure
5). The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222, Lys1239, Ser1293,
Glu1296 and Met1297 were found to interact with the non-structural protein sequence complex
14

to be cleaved, and were considered an individual functional unit. Only two residues are located
in the N-domain, Gln1039 and Lys1045, with all the other residues located in the C-domain.
Analogous work by Bassetto et al.71 reported the development of a homology model for the
nsP2 protease active site within the C-domain.
The predicted active site by Singh Kh et al.69 and Bassetto et al.71 matches with the
above mentioned explanation of the positioning of the active site within the C-domain. In
particular, they found the His1222 residue to be lying within the predicted active site pocket.
Analysis of the enzyme surface shows that the predicted active site is located in a major surface
groove as shown in Figure 6, with the major cavity on the enzyme surface more likely to
accommodate the substrate polyprotein sequence to be cleaved.

Figure 6. Electrostatic potential surface of the CHIKV nsP2 and its active site pocket within the
C-domain, a) The active enzyme surface front view showing the active site as a transparent red
sphere surrounding the active site with the Cys1233 and His1222 residues lying within the
sphere. b) Side view of the enzyme (rotated to the left by 90º about the vertical axis from the
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view in a) showing the major accessible cavity to the active site with a part of the sphere
protruding toward the outer surface, generated from the pdb file 3TRK.
This major enzyme groove (Figure 6b) may act as the enzyme mouth holding the protein
to be processed. Therefore, targeting the residues identified above,69 as well as the residues
within the active site, would be applicable strategy to inhibit the enzyme function and
consequently inhibiting the virus replication.
Moreover, the alphaviruses nsP2 proteins have been described as virulence factors
responsible for the transcriptional and translational shutoff in infected host cells and the
inhibition of interferon (IFN)-mediated antiviral responses contributing to the controlling of
translational machinery by viral factors.72,73 This controlling comes through interactions with
cellular RNA binding proteins, including heterogeneous nuclear ribonucleoproteins (hnRNPs),
ribosomal protein S6 (RpS6), and cellular filament components. Recently reported was the
believed interaction of 22 cellular components with nsP2 or nsP4, contributing to the CHIKV
replication, mainly heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and ubiquilin 4
(UBQLN4). It was also noted that the interaction of nsP2 with the tetratricopeptide repeat
protein 7B (TTC7B) plays a significant role in the cellular machinery control induced by the
CHIKV infection.74
II.1.3. Non-structural protein 3. The function of alphaviruses nsP3 remains unknown,
although mutations can affect different steps of the viral replication machinery.75 It is
constructed of two domains, the first being a unique macro domain in the conserved N-terminal
region. The C-terminal region is less conserved and is phosphorylated in approximately 16
positions on serines and threonines.76,77 The function of phosphorylation is not understood, but it
was found that deletion of these phosphorylated residues decreases the level of RNA synthesis.78
Interestingly, viral pathogenicity of Semliki Forest virus (SFV), another alphavirus, is decreased
16

in absence of that phosphorylation on the nsP3, and the absence of the C terminus alters SFV
neurovirulence.79
The N-terminus of nsP3 contains a macro domain (known also as the X domain), which
binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose-1``phosphate,80,81 a side product of cellular pre-tRNA splicing. Therefore, it is believed to control
the metabolism of ADP-ribose 1``- phosphate and/or other ADP-ribose derivatives which have
regulatory functions in the cell. The ADP ribose–binding site within the nsP3 macro domain is
solvent-exposed and points away from the other domains in the nsP23 polyprotein. Based on
sequence conservation in alphaviruses, it has been shown that residues just after the nsP3 macro
domain play a role in positioning of the nsP23 complex cleavage site.82 It can be inferred from
the crystal structure of the nsP23 precursor protein of the closely related alphaviruses, SINV,
that the nsP2 is connected to the nsP3 through the macro domain of the nsP3.83 The nsP23
cleavage site is located in a narrow cleft formed between nsP2 and nsP3 that is inaccessible for
proteolysis, and all the nsP2 non-cytopathic mutants lie at the interface between nsP2 and
nsP3.83 The inaccessibility of the nsP23 cleavage site indicates that access is tightly regulated. It
is believed that the activator segment is located in the amino-terminus of the nsP2 which
becomes exposed after cleavage from the nsP12 precursor poly protein.84
In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was solved80
(Figure 7). It consists of 672 residues and contains six-stranded β sheets with three α helices.
The intermolecular interactions between the residues in the binding pocket of the enzyme and
the ADP-ribose,85 as analysed from the crystal structure, are shown in Figure 8.
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Figure 7. Crystal structure of the CHIKV macro domain with the bound ADP-ribose (yellow
colour), generated from the pdb file code: 3GPO.

Figure 8. 2D representation of the interaction of ADP-ribose inside the nsP3 macro domain
binding pocket showing the other residues inside the active site (Generated from the pdb file:
3GPO).
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As shown in Figure 8, the key binding residues are: Arg144, Asp10, Ile11 Thr111, Gly112,
Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding complex is formed of 10 Hbonds and one π-cation interaction.85 The PO42− moiety showed the strongest interactions with
these residues in the enzyme pocket. Also, the ribose (with Thr111) and the diphosphate (with
Val 33, Ser110, Gly112, Val113, Tyr114) units were found to play major roles in the CHIKV
nsP3 ADP-ribose complex.85
Understanding this binding interaction of the ADP-ribose to the macro domain of the CHIKV
could therefore be a useful element to further assist in drug design and development of inhibitors
for this virus. Bound inhibitors to the ADP-ribose binding pocket will alter the function of the
nsP3 either cleaved or in a polyprotein complex, and consequently will alter the function of the
viral replication machinery.
Recently, more insights on the molecular function of the nsP3 revealed interesting findings, it
was reported that the nsP3 of CHKV, as with other alphaviruses, use a conserved proline-rich
motif to interact with the Src-homology-3 (SH3) domain of amphiphysin-1 and amphiphysin-2
proteins of the host cell, two related member proteins of the BAR (Bin-Amphiphysin-Rvsp)
protein superfamily implicated in several cellular functions.86
More recently,87 the nsP3 has been shown to be the inhibitor of stress granule assembly by
recruiting G3BP into cytoplasmic foci. The conserved nsP3 SH3 domain-binding motif (the
proline-rich motif) is essential for both nsP3-G3BP interactions and viral RNA replication.
G3BP (Ras GTPase-activating protein-binding protein) is an enzyme in human cells and a
member of the heterogeneous nuclear RNA-binding proteins.88 This protein plays a major role
during infection and in the assembly of stress granules. Stress granules are membranous
cytoplasmic focal structures (foci) that immediately aggregate in response to cellular stress. This
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last action leads to impaired translation of most mRNAs.89 These stress granules may have
antiviral activity that is inhibited by CHIKV replication by the nsP3 SH3 domain-binding
motif.87
II.1.4. Non-structural protein 4. The non-structural protein 4 was identified as the RNAdependent-RNA polymerase,29,90 and was recently found to suppress the host cell unfold protein
response (UPR), also named as the endoplasmic reticulum (ER) stress response.91 The UPR is a
mechanism that maintains the cellular protein homeostasis and prevents over-loading of
unfolded protein in the lumen of the ER during normal and diseased cellular conditions. The
UPR is multi-stepped and involves contributing proteins, including the PKR-like ER kinases
(PERK).92 During the UPR, PERK is activated by self-dimerization and phosphorylation, which
then phosphorylates the serine 51 position of the eukaryotic translation initiation factor 2, alpha
subunit (eIF2α), an essential factor for protein synthesis. Phosphorylated eIF2α inhibits the
general protein synthesis, and consequently, will inhibit the pathogen protein replication. The
CHIKV nsP4 was found experimentally to significantly reduce the phosphorylation (serine 51)
of eIF2α, and thus ensuring the translation of the viral protein.91 This discovery can be exploited
as possible target for anti-CHIKV intervention. The crystal structure of the CHIKV nsP4 is not
yet available for the structure based inhibitors discovery, and more efforts should be devoted to
decipher the mechanism of action for that protein as well as experimental tools to evaluate
possible potential protein inhibitors.
II.2. Structural Proteins
The invasion of susceptible cells by the CHIKV is performed by two viral glycoproteins, E1 and
E2. Both carry the basic antigenic determinants and form the icosahedral shell of the virion
particle. E2 and E3 are produced from furin cleavage of the p62 (also known as PE2, see Figure
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2) precursor. E2 is responsible for receptor binding whereas E1 mediates the membrane fusion.10
E3 contains the 64-amino-terminal residues of p62.93
E1 and p62 peptide are type I membrane proteins and are derived from a structural
polyprotein precursor. They are translated in the infected cell endoplasmic reticulum, into a
p62–E1 heterodimer and processed by the Golgi (Figure 3). E3 protects the E2-E1 heterodimer
from premature fusion with cellular membranes.94 The heterodimers trimerize forming the viral
spikes. Cleavage of p62 into E3 and E2 during transport to the cell surface prepares the spikes
for the fusogenic activation to enter the cell. At the plasma membrane, the formed virions bud
through interactions between E2 and genome-containing viral nucleocapsids in the cytoplasm.95
In a recent study, the roles of four amino acid residues (G91, V178, A226, and H230) in
the CHIKV E1 protein were linked to the E1 and cell fusion process.96 The study revealed that
the highly conserved amino acid residues, G91 and H230, were important for membrane fusion
functionality. The glycine residue (G91) is critical for the fusion process whereas any mutation
or substitution in this residue lead to complete loss of E1 fusion ability. The E1 histidine 230 is
located outside of the fusion sequence, but still critical for the fusion. Other structural proteins
also affect the E1 fusogenic capacity, e.g. the E2 protein facilitates both E1 folding and regulates
E1 fusogenic properties in a pH and cholesterol dependent process.96 As an alphavirus family
member, the hydrophobic fusion peptide of the CHIKV was found to be a trimer of hairpins
composed of β-sheets in the post fusion state (type II fusion proteins).97,98 Figure 9 shows the
crystal structure of the CHIKV fusion peptide,99 consisting of 18 amino acid residues, which are
residues 84−101 in the full-length E1 glycoprotein.95
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Figure 9. Hydrophobic surface view of the CHIKV fusion peptide showing the residue G91 in
red label located at the back side (generated from the crystal structure of the fusion peptide, pdb
file code: 2RSW99).

The crystal structures of the CHIKV p62-E1 (immature) and the E3-E2-E1 (mature)
glycoprotein complexes are shown in Figures 10-12. E1 is folded into three domains I, II and III
(Figure 11) that are rich in β-sheets. E2 is an immunoglobulin β protein, with three domains (A,
B and C). Domain A is at the centre and domain B is at the membrane upper end whereas
domain C is towards the viral membrane. The latter binds to domain II of E1 by hydrogen
bonding due to the hydrophilic contact region between them (Figure 10). The long β – ribbon of
E2 makes most of the connection with E3 (Figure 12). Furin loop (Figure 10) is the E2E3
junction in the immature complex, this junction contains a functional proprotein convertase
motif which is cleaved by the cellular proteases, furin-like proprotein convertases, during the
maturation (Figure 3) of the glycoproteins.42 Variations within this junction site among the
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different CHIKV isolates greatly affect the cleavage susceptibility by furin proteases. The amino
acid His60 (residue 56 in the crystal structure pdb file: 3N40) is the critical residue that
determines the spectrum of furin and furin-like convertases that process E2E3 glycoprotein
complexes.100 It can be inferred from the comparison between the immature and the mature
glycoprotein complexes structures,95 that the short peptide sequence (Pro59, His60, Arg63,
Glu64, Ser65, Thr66, Lys67 and Asp68) is cleaved form the immature complex after furin
cleavage.

Figure 10. Crystal structure of the immature envelope glycoprotein complex of Chikungunya
virus, E1 is formed from domains I, II and III. E2 contains domains A, B and C. Structure
generated from the pdb file code: 3N4095. E3 stabilizes the E2 β–ribbon connector94 being
associated with domain A of E2 and domain II of E1, allowing domain B to protect the fusion
loop.

The U shaped fusion loop of E1 is inserted in a cavity that lies between the E2 domains
A and B, being stabilized by hydrogen bonds (Figure 13) with E2 histidine side chains.95 At
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neutral pH, E3 maintains the relative orientation of E2 domains B and A creating a cavity space
that accommodates the E1 fusion loop. This orientation by E3 protects the virus from premature
fusion with other cellular membranes.95,101 The fusogenic activity of the E1 fusion peptide is
therefore highly dependent on pH change. The histidine residues of E2 act as the pH sensor for
the activation of the fusion protein at lower pH95 due to the increased probability of histidines to
become positively charged at lower pH values (acidic endosome), based on the fact that the
imidazole ring of the histidine residue is the only amino acid side chain whose apparent
dissociation constant from protons (pKa) falls within the physiological range.

Figure 11. Crystal structure of E1 glycoprotein formed of 393 residues (residue 402-residue 794
within the whole complex structure), separated from the complex for visualization, generated
from the pdb file code: 3N4095.
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Figure 12. Crystal structure of E2, E3 glycoprotein complex formed of 401 residues (residue 1residue 401 within the whole structural protein complex), separated from the complex for
visualization. Generated from the pdb file code: 3N4095.

Some important locations (transitional epitopes) were identified in both E1 (domain III)
and E2 (domain B) of alphaviruses: these locations become accessible upon exposure to heat or
low pH102,103 as well as upon contact of the virions with the susceptible cells. This contact leads
to conformational changes related to cell binding,104 with domain B moving out in relation to
domain A, thus opening the cavity. The fusion loop now becomes free to release,95 without a full
dissociation of the E2–E1 heterodimer. Other residues in domain B of E2 are believed to be
associated with cell recognition assuming that a number of sites on the virus surface can interact
with different cell surface receptors, and may be involved in the attachment and entry of the
virus.94
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Figure 13. Crystal structure of the CHIKV mature envelope glycoprotein complex. E1 is viewed
as hydrophobic surface with the critical amino acid residue Gly9199 of the fusion loop labelled in
black. E2 and E3 are viewed as a solid ribbon, and histidine residues on E2 are viewed as stick
structures in red surrounding the fusion loop and acting as the pH sensors.95 Generated from the
pdb file code: 3N4295.

Recently, the possible druggable pockets within the CHIKV envelope proteins have been
determined (Figure 14), with two found to be critical to the protein functions, mainly the fusion
process.105 The green pocket (Figure 14) represents a surface cavity that lies between the E1
domain II and E2 β–ribbon that connects E2 domain A to E2 domain C. It extends downwards
as a channel between E1 domain II and E2 domain A. The blue pocket (Figure 14) is a narrow
channel extending just behind the fusion loop and is surrounded by both E2 domains A and B.
These pockets make contact with residues from E1 and E2 and therefore, ligands for these
pockets can affect the relative movement of E1 and E2 domains in the pre- and post-fusion
states. Furthermore, the blue pocket (Figure 14) makes contact with the fusion loop residues,
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and therefore, designing antagonists for this pocket with would be applicable strategy to block
the fusion function.105

Figure 14. Possible druggable cavities within the CHIKV envelope proteins illustrated as blue
and green space-filling pockets. E1 is coloured in violet, E2 is coloured in orange and E3 is
shown in red. For simplicity, the figure illustrates only a component of the glycoprotein mature
envelope complex. Generated from the pdb file code: 3N4295.

II.3. Highlights for the CHIKV target enzymes
With the recent growing knowledge and available structural information about the CHIKV
genome, drug design of specific inhibitors targeting individual viral proteins has become more
viable. The most promising targets from a chemical and biological standpoint would be the viral
protease (nsP2) and the viral envelope proteins. The first protein has a complete crystal structure
for the N and C domains, with the critical residues for proteolytic activity already investigated.
This nsP2 protein also functions through the N domain, allowing the possibility of medicinal
chemistry intervention at both domains on this protein. The challenge is the current lack of
individual enzyme-based assays to investigate the inhibitory effects of the designed protein
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antagonists, rather than the whole cell assay protocols. The second promising protein target is
the viral envelope proteins where specific residues have been identified to be essential for the
viral fusion process, e.g. the Gly91 and His230 residues. Designing specific inhibitors targeting
the viral fusion process would be valuable for the inhibition of alphaviruses in general. The viral
nsP3 also represents a possible drug design target, with the structure of the conserved macro
domain is already known. However, this target requires further investigation, e.g. the solving of
the complete protein structure.
III. DEVELOPMENT OF CHEMOTHERAPEUTICS AGAINST CHIKV: NEW
MEDICINAL CHEMISTRY LEADS
There is currently no recognised single antiviral treatment for chikungunya. During the recent
outbreaks that occurred in the Indian Ocean nations, only treatments for symptoms were
available, based on non-steroidal anti-inflammatory, non-salicylate analgesics and fluids. Mild
physical exercise is believed to decrease the joint stiffness, but heavy exercise may increase the
rheumatic pain. During chronic CHIKV infection, corticosteroids may be used to help decrease
the inflammation.106 The status of drug discovery for the CHIKV is still in the very early stages
with no drugs currently in clinical trials. The first mouse model to study the pathophysiology of
the resulting disease was developed in 2008,107 after which several animal models were
developed to aid the understanding of the drug-disease interactions that would facilitate the
development of effective therapy.108
III.1. Protease inhibitors. Targeting the CHIKV nsP2 protease activity within the C-domain,
would have an inhibitory effect on the viral replication. Using the developed homology model
for the nsP2, Singh Kh and co-workers screened a library of compounds in silico and identified
four compounds (1-4, Figure 15) as potential inhibitors of the nsP2 protease.69 Ideally, binding
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to this active site will block protein function stopping the replication cycle. However, the
antiviral activity of these hits has yet to been reported.

Figure 15. Structures of the four in silico predicted CHIKV nsP2 inhibitors.

In a similar work, Bassetto et al.71 reported the identification of in silico CHIKV nsP2
inhibitors through a virtual screening of a large compounds library using the developed
homology model for the CHIKV nsP2. One of the hits, compound (5, Figure 16) was predicted
to bind to central portion of the nsP2 protease active site, with its hydrazone group placed in the
region defined by the catalytic dyad. The in vitro activity of this hit compound was assessed and
it was found to inhibit the virus at EC50 value of 5 µM with a selectivity index (SI) value of 14,
through the inhibition of the virus-induced cytopathic effect.71 The central cyclopropyl and the
hydrazone moieties were found, through a structure activity relationship study, to be important
for the anti-chikungunya activity. A series of derivatives were also designed based on these
identified pharmacophores of (5), whereas the cyclopropyl group was replaced with a trans29

ethenylic moiety (6, Figure 16), maintaining length and geometry of the original linker. The
antiviral activity was slightly improved with (6) displaying an EC50 value of 3.2 µM and a
selectivity index (SI) of 32. The binding modes of both compounds (5, 6) inside the nsP2 pocket
were similar.71

Figure 16. Chemical structures of the CHIKV inhibitors identified from in silico screening, with
subsequent testing confirming substantial activities. Red circles indicate the only difference in
the structures responsible for the activity change.

III.2. Furin inhibitors. Infection by alphaviruses can be inhibited in vitro by blocking the
intracellular furin-mediated cleavage of viral envelope glycoproteins: the E2E3 or p62
precursors. This blocking was demonstrated by showing the inhibitory effect of an irreversible
furin-inhibiting peptide, decanoyl-RVKR-chloromethyl ketone (dec-RVKR-cmk, 7, Figure 17)
on in vitro CHIKV infection.100 This peptide significantly reduced the processing of E3E2
CHIKV glycoproteins in infected myoblast cultures and led to the formation of immature viral
particles and impaired viral spreading among cells, but not the replication in cells already
infected.100 Therefore, the chemical structure of the furin-inhibiting peptide (7) could be a
starting point for generating novel generations of active peptidomimetics using the ligand-based
drug design techniques, targeting the intracellular furin cleavage step.
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Figure 17. Structures of the CHIKV furin-inhibiting peptide (7).

III.3. Chloroquine and Quinine. The in vitro antiviral activity of chloroquine (8, Figure 18)
was first reported more than 35 years ago and has been successfully used as an anti-malarial
drug.109,110 With respect to the alphaviruses, chloroquine was found to be effective in
vitro,111,112,113 however, recently a mouse model revealed that chloroquine may enhance viral
replication in vivo leading to aggravation of the disease.114 Regarding the CHIKF, chloroquine
and chloroquine phosphate have been used in the treatment of chronic chikungunya arthritis,115
but only for the anti-inflammatory properties of the molecule (used in chronic rheumatologic
diseases) rather than for any antiviral effect. Some studies suggest that chloroquine might
interact with the endosome-mediated internalisation process during the infection cycle, stating
that chloroquine might be classified as an entry inhibitor. Compound 8 entered phase 3 clinical
trials in France as a therapy for the CHIKV in 2006, however, these studies were terminated in
2007 with no definite anti-viral results.
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Figure 18. The structure and reported anti-CHIKV activities of the quinolines 8 and 9.

In one clinical study, the effect of 8 on CHIKF patients was investigated using another
placebo treated group of patients, and at the conclusion, there was no statistical difference
between the chloroquine and the placebo treated groups regarding the mean duration of febrile
arthralgia or the decrease of viraemia (viral count in plasma).
Another anti-malarial drug, quinine (9, Figure 18), also inhibits the virus in vitro at a
concentration less than that of chloroquine (IC50 = 0.1 µg/ml for quinine, 1.1 µg/ml for
chloroquine). Also, quinine is suggested to affect the nsP1 as mutations in this protein occur
upon growing the virus in a high concentrations of quinine.106
Overall, the contradicting results from different studies casts serious doubt as to the
effectiveness of chloroquine as an effective chemotherapeutic against CHIKV and until
resolved, it should be treated with caution as a drug lead.106

III.4. Ribavirin and 6-Azauridine. The antiviral ribavirin (10, Figure 19), is well known to
inhibit in vitro many RNA viruses, by different mechanisms.116 It is being used either alone for
treatment of infections as Respiratory Syncytial virus, or in combination with alpha-interferon in
the treatment of hepatitis C virus (HCV) infection. This combination showed a synergistic effect
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in vitro in the inhibition of CHIKV.117 A combination of alpha-interferon, at a concentration of
3.9 IU/ml, and ribavirin at a concentration of 18.75 µg/ml, inhibited CHIKV replication by 50%,
whereas 10 alone without interferon, inhibited CHIKV with EC50 value of 83.3 µg/ml. However,
there is no evidence supporting the clinical efficacy of 10 on CHIKV, and the combination with
interferon should be subjected to clinical trials for the treatment of CHIKV infections.106
Furthermore, the exact mechanism of ribavirin is still unclear as it may change from virus to
another, however, it is believed that ribavirin can interact with the intracellular viral RNA
production.

Figure 19. The structure of nucleosides 10 and 11.

The broad-spectrum anti-metabolite, 6-azauridine (11, Figure 19) inhibits both DNA and
RNA virus replication, and the activity might be through the inhibition of orotidine
monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine,
cytidine and thymidine.118 It showed a significant inhibition of CHIKV at a low concentration
(0.2 µg/ml) and was more effective against the CHIKV compared to 10.117 Compound 11 is not
approved for human use and therefore was not included in a combination study with alphainterferon. However, the corresponding 6-azauridine triacetate is used for treatment of different
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diseases without notable adverse effects.119 Therefore, 6-azauridine should be evaluated in vivo
as CHIKV inhibitor.117
III.5. Arbidol. The antiviral drug arbidol (12, Figure 20) was originally developed 20 years ago
at the Russian Research Chemical and Pharmaceutical Institute.120 Since 1990, it has been used
in Russia for acute respiratory infections including influenza. So far, arbidol shows a wide range
of activity against many RNA, DNA, enveloped and non-enveloped viruses.121 This broad
spectrum of activity may be attributed to the different modes of actions including the inhibition
of virus mediated fusion,122 and blocking of the viral entry into the target cells through inhibition
of glycoprotein conformational changes that are essential for the fusion process, as in case of
influenza virus and hepatitis C virus.123,124
In 2011, 12 and two derived metabolites (Figure 20), 13 (HZ1) and 14 (HZ3), were
tested in vitro on the chikungunya virus using two cell lines, and under different conditions (pre
and post-infection treatments). The only active compound was 12 with an IC50 value much lower
than the toxic concentration (IC50 = 12.2 µM, CC50 > 200 µg/ml).125 Compounds 13 and 14 were
assumed to be responsible for the anti-viral properties of arbidol, however in this study, they
showed only weak effects on CHIKV replication.

Figure 20. The structures of indole-based derivatives 12, 13 and 14.

34

Compound 12 was found to be not viricidal, rather, it blocks the earliest stages of the
viral replication, virus attachment and/or virus entry as previously reported.121 For CHIKV, it
works by targeting the cellular membrane (E2 viral envelope protein) which was confirmed by
the use of an arbidol resistant CHIKV strain (mutation in the E2 protein, G407R).125 However,
all these studies were performed in vitro and in vivo studies are required to validate the activity
of arbidol on CHIKV.
III.6. Mycophenolic acid (MPA). Mycophenolic acid (15, Figure 21) was isolated
approximately one hundred years ago.126 It acts as an inhibitor for the inosine monophosphate
dehydrogenase (IMPDH), an enzyme evolved in the de novo biosynthesis of guanine nucleotide.
It has a good anti-proliferation activity and has been established as an anticancer127 and antiviral
agent, and as an immunosuppressant.128

Figure 21. The structures of inhibitors of IMPDH, 15 and 16.
Recently, 15 was shown to inhibit the CHIKV replication by virus induced cell death.
The IC50 value was 0.2 µM with a selectivity index of 150,129 and it was found to induce CHIKV
apoptosis. When the treated CHIKV infected cells were provided with exogenous guanosine
(GMP), 15 could no more prevent the CHIKV induced cell death, indicating that it worked by
inhibiting the IMPDH enzyme. It is also suggested that 15 increases the mutation rate during the
35

viral replication.129 Considered as a good lead compound, the in vivo activity of 15 on CHIKV
requires further investigation as it is known that the compound suffers from a metabolic
drawback associated with rapid conjugation of the C-7 phenolic hydroxyl group with glucuronic
acid.130,131
III.7. Trigocherrin A. Trigocherrin A (16, Figure 21), is a highly oxygenated and chlorinated
daphnane diterpenoid orthoester, that had been isolated from the bark of Trigonostemon
cherrieri Veillon (Euphorbiaceae), a tree collected in the sclerophyllous forest of NewCaledonia. This genus comprises about 80 species occurring in tropical Asia, from India and Sri
Lanka to New Guinea.132 These diterpenoids have been shown to have cytotoxic133,134 and
antiviral135,136 properties. Recently, this natural product was tested against CHIKV and was
found to inhibit virus-induced cell death in a virus-cell-based assay with an EC50 of 1.5 μM and
only caused significant anti-metabolic effects at a concentration (CC50) of 35 μM. The
selectivity index (SI) value was 24. Different concentrations of 16 were able to protect the host
cells from the virus cytopathic effect without any adverse side-effects. It was also found to be
more potent than the reference compound used in this study (8).137,138 The assay protocol
suggests that this compound might inhibit the viral replicase functions, however, for the drug
discovery process, both the in vivo activity, the precise mode of action as well as the total
synthesis of this lead compound should be investigated.
III.8. Trigowiin A, Prostratin and 12‑O‑Tetradecanoylphorbol 13-Acetate. In late 2012, ,
an extract from the bark of Trigonostemon howii from the Euphorbiaceae species out of central
Vietnam was tested against the CHIKV.139 A new tigliane diterpenoid, trigowiin A (17, Figure
22) was isolated and was found to be structurally closely related to the tigliane diterpenes
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(Figure 22), prostratin (a promising adjuvant for anti-HIV therapy)140 (18) and 12-Otetradecanoylphorbol 13-acetate (19).139

Figure 22. Chemical structures of 17, 18 and 19.

In a CHIKV assay, 17 showed weak antiviral activity, with an EC50 of 43.5 ± 12.8 μM
whereas 19 and 18 proved to be the most potent inhibitors, with low EC50 values and higher
selectivity indices (SI), for 19, EC50 = 0.0029 ± 0.0003 μM and SI = 1965 while the EC50 for 18
was 2.6 ± 1.5 μM and SI = 30.3 showing that 19 was 65 times more potent than 18.139 At the
same time, these compounds did not show activity against the Sindbis virus (SINV) nor the
Semliki forest virus (SFV) which indicates an excellent selectivity for inhibition of the CHIKV.
The authors139 believe that this selectivity for 19 might be due to a specific mechanism of virus
inhibition through the activation of the signal transduction enzyme protein kinase C (PKC),
similar to the proposed mechanism of HIV replication inhibition.141 However, 19 currently is
one of the most potent tumor-promoting agents known to date,142 therefore, the less potent 18 is
more likely to be further investigated as a potential candidate, especially as it is shown not to be
a tumor-promoting agent. The exact mode of action of these compounds is currently unknown
and needs further investigation.
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III.9. Lupenone and β-amyrone. In the continuous effort to identify novel inhibitors of
Chikungunya from natural sources, a phytochemical study on the leaves of Anacolosa
pervilleana (Madagascan plant) was performed in a virus-cell-based assay for CHIKV.144 The
triterpenoids isolated showed moderate anti-CHIKV activity (Figure 23) (lupenone (20) EC50 =
77 μM and β-amyrone (21) EC50 value of 86 μM).144 Due to their weak activity, these natural
products require medicinal chemistry optimization before being considered as promising lead
compounds.
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Figure 23. Chemical structures of 20 and 21.

III.10. Harringtonine. Harringtonine (22, Figure 24) is an alkaloid from Cephalotaxus
harringtonia trees, which is native to Japan and it has a known antitumor activity. It is known to
inhibit the first cycle of the elongation phase of eukaryotic translation.145 It was shown
recently146 that 22 displayed potent inhibition of CHIKV infection (EC50 = 0.24 μM) with
minimal cytotoxicity, through the inhibition of the early stages of infection after cellular
endocytosis. Also, it was found to affect the CHIKV RNA production inside the infected cell, as
well as viral protein expression such as the nsP3 and the E2 proteins.146 The in vivo studies of 22
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are still ongoing which could make it a promising lead towards the discovery of anti-CHIKV
drugs.
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Figure 24. Chemical structure of the alkaloid 22.

III.11. Purine based inhibitors. In 2012, D’hooghe et al. reported the design and synthesis of a
new series of purine-β-lactam hybrids and purine-aminopropanol hybrids and their evaluation as
potential antiviral candidates depending on the antiviral templates purines and β-lactams.147
These new scaffolds were screened against nine different viruses including the chikungunya
virus. Two purine-β-lactam hybrids and one purine-aminopropanol hybrid (Figure 25) were
found to possess promising activity and cytotoxicity profiles, the purine-β-lactam (23) with EC50
= 17.11 μM and SI > 5.75, the purine-β-lactam (24) with EC50 = 13.01 μM and SI > 4 and the
purine-aminopropanol (25) with EC50 = 11.51 μM and SI > 6.147 The mode of action has not
been investigated. The synthesis of this class of compounds is already established and therefore,
they represent good subject for further medicinal chemistry optimization.
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Figure 25. Chemical structures of 23, 24 and 25.

III.12. Polyinosinic acid. Polycytidylic acid [Poly (I:C)] (26, Figure 26), a synthetic doublestranded RNA (dsRNA) analogue, is an immunostimulant acting as an inducer for the most
potent interferon (IFN) via interaction with the toll-like receptor 3 (TLR3).148 It can induce IFNα/β production and natural killer (NK) cells activation in vivo after intraperitoneal injection.149
Activation of the TLR3 contributes to an innate immune response against many viruses.150 In
CHIKV infection, the virus was found to be sensitive to the innate immune response induced by
26. This sensitivity was noticed as a decreased cytopathic effect and inhibition of the virus
replication in the infected cell lines. This sensitivity has been explained to be a result of the
overstimulation of the TTLR3 as well as the other anti-viral genes by 26.151
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Figure 26. The structure of the dsRNA analogue 26.
III.13. Gene silencers. New trends in the CHIKV treatment trials are the use of genes silencers
targeting specific viral proteins (capsid protein, E1, nsP1 and nsP3). Silencing the target viral
genes will consequently lead to the shutdown of the protein expression process, and thereby
stopping viral replication. After viral infection, the exogenous small interfering RNA (siRNA)
induces RNA interference mechanism, resulting in the assembly of the RNA-induced silencing
complex (RISC) which inhibits subsequent protein expression. Using the siRNA targeting
CHIKV E1 and nsP3 effectively suppressed in vitro CHIKV replication.152 Similarly, a plasmid
based small hairpin RNA (shRNA) against CHIKV replication targeting the capsid, E1 and nsP1
proteins has been used. Simply, the plasmid is introduced to cell and expressed inside the
nucleus, resulting in the formation of small-hairpin RNA (shRNA) which are processed by the
cytoplasmic Dicer enzyme to siRNAs, leading to activation of the RNA silencing machinery.
This silencing machinery recognizes and degrades the target CHIKV single strand RNA,
consequently stopping viral protein expression.153 Clinical studies should be able to prove the
applicability of these trends in developing effective anti-CHIKV therapeutics.
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III.14. Envelope protein antagonists. Targeting the CHIKV envelope proteins,105 possible in
silico antagonists have been reported based on predicted binding sites. Compounds 27-30
(Figure 27) were projected to interact with the CHIKV envelope residues critical for the fusion
process. The (S)-stereochemistry of the OH group in 28-30 was found to be important for the in
silico binding.105 The antiviral activity for these compounds is yet to be evaluated.

Figure 27. The identified in silico antagonists for the CHIKV envelope proteins.

IV. HIGHLIGHTS FOR CHIKV INHIBITORS
Several molecules have been tested against the emerging CHIKV with weak to moderate
activities. Those included drugs already in the market, being used for other diseases, such as 8,
10, 12 and 15. The challenge here is evolving these structures onto more novel molecules with
improved potency and maintaining any drug-like qualities. The putative protease inhibitors (5,
6) and the predicted fusion inhibitors (27-30) developed would be attractive candidates for
further investigation, however, the challenge lies in being able to identify specific enzyme assay
protocols to confirm the selectivity for the specific viral proteins. Protein crystallization with the
inhibitor would be a useful element to validate such studies. Some of the tested compounds
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represent complex natural products and have sufficient activity as antiviral agents, such as 16,
18, 19 and 22. It will be a significant task to chemically access these structures and to simplify
the chemical skeletons to more drug like molecules with acceptable ADME properties.
The anti-CHIKV activity of the tested molecules ranged from strong to weak inhibition
depending on the type of the assay used, with the 19 being the strongest inhibitor with EC50 =
0.0029 μM and 20 which displayed the weakest activity with EC50 = 86 μM, similar activity to
that of 10, EC50 = 83.3 μM. It is worth noting that the active agents, 19 and the less active 16,
shared a common structural feature, the substituted benzo[e]azulene derived structure, (Figure
27). The structure of 19 is simpler than that of 16, lacking the extra phenyl rings, two chlorine
atoms, four oxygen bridges and the alkene side chain (Figure 27), however, 19 has a
characteristic long tetradecanoic ester moiety which was responsible for the activity over 17 and
18, two derivatives that were even less active than 16.

Figure 27. Chemical structures of 19 and 16. The common skeleton is highlighted in bold red
colour, and groups unique to 19 are shown in green while the excess groups of 16 are shown in
blue colour.
V. CONCLUDING REMARKS
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Chikungunya virus (CHIKV) is an emerging arbovirus that has had devastating effects in recent
years in wide ranging areas around the world. Chikungunya virus infection can develop into an
arthritis disease that remains with the patient for years. The mutations in the viral envelope
protein genes increased the fitness of the virus in another mosquito vector, Ae. albopictus which
was responsible for cases reported in temperate zones. With no licensed vaccine for
immunization against this virus, disease control is currently non-existent, and the defence line
would be through the development of chemotherapeutics. Some promising lead compounds have
been discovered recently and could be starting points towards effective treatments. The
discovery of these leads was mostly based on random screening of drugs already in the market,
newly discovered natural products or the antiviral evaluation of synthetic compounds. Also, in
the last two years, the molecular function as well as the crystal structures of a number of critical
enzymes involved in the virus life cycle have been reported, with no known specific inhibitors
thus far. Some in silico screens against these proteins have been performed, and while
compounds with antiviral activity have been identified, their mechanism has yet to be
confirmed. Substantial medicinal chemistry efforts will be required to advance drug discovery
and development in this area. Further, despite the availability of whole cell anti-CHIKV testing,
the development of individual CHIKV enzyme assays would greatly benefit SAR research
programs as well as helping to identify targets for newly discovered inhibitors. Considering the
neglected status of this virus and the emerging knowledge of the biology of CHIKV, the
opportunity for small molecule inhibitors to be discovered and developed remains high.
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Ubiquilin 4; UPR, Unfold Protein Response.

References
1.

Her, Z.; Kam, Y. W.; Lin, R. T.; Ng, L. F. Chikungunya: a bending reality. Microbes Infect.
2009, 11, 1165-1176.

2.

Robinson, M. C. An epidemic of virus disease in Southern Province, Tanganyika Territory,
in 1952-53. I. Clinical features. Trans. R. Soc. Trop. Med. Hyg. 1955, 49, 28-32.
46

3.

Lumsden, W. H. An epidemic of virus disease in Southern Province, Tanganyika Territory,
in 1952-53. II. General description and epidemiology. Trans. R. Soc. Trop. Med. Hyg. 1955,
49, 33-57.

4.

Nimmannitya, S.; Halstead, S. B.; Cohen, S. N.; Margiotta, M. R. Dengue and chikungunya
virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with
hemorrhagic fever. Am. J. Trop. Med. Hyg. 1969, 18, 954-971.

5.

Njenga, M. K.; Nderitu, L.; Ledermann, J. P.; Ndirangu, A.; Logue, C. H.; Kelly, C. H. L.;
Sang, R.; Sergon, K.; Breiman, R.; Powers, A. M. Tracking epidemic Chikungunya virus
into the Indian Ocean from East Africa. J. Gen. Virol. 2008, 89, 2754-2760.

6.

Ravi, V. Re-emergence of chikungunya virus in India. Indian J. Med. Microbio. 2006, 24,
83-84.

7.

Sambri, V.; Cavrini, F.; Rossini, G.; Pierro, A.; Landini, M. P. The 2007 epidemic outbreak
of Chikungunya virus infection in the Romagna region of Italy: a new perspective for the
possible diffusion of tropical diseases in temperate areas? New Microbiol. 2008, 31, 303304.

8.

Enserink, M. Infectious diseases - Chikungunya: No longer a Third World disease. Science
2007, 318, 1860-1861.

9.

Powers, A. M.; Logue, C. H. Changing patterns of chikungunya virus: re-emergence of a
zoonotic arbovirus. J. Gen. Virol. 2007, 88, 2363-2377.

10. Schwartz, O.; Albert, M. L. Biology and pathogenesis of chikungunya virus. Nat. Rev.
Microbiol. 2010, 8, 491-500.
11. Outbreak news. Chikungunya, India. Releve epidemiologique hebdomadaire / Section
d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record /
Health Section of the Secretariat of the League of Nations 2006, 81, 409-410.
47

12. Saxena, S. K.; Singh, M.; Mishra, N.; Lakshmi, V. Resurgence of chikungunya virus in
India: an emerging threat. Euro. Surveill. 2006, 11, E060810 2.
13. Chhabra, M.; Mittal, V.; Bhattacharya, D.; Rana, U.; Lal, S. Chikungunya fever: a reemerging viral infection. Indian J. Med. Microbiol. 2008, 26, 5-12.
14. Vazeille, M.; Moutailler, S.; Coudrier, D.; Rousseaux, C.; Khun, H.; Huerre, M.; Thiria, J.;
Dehecq, J. S.; Fontenille, D.; Schuffenecker, I.; Despres, P.; Failloux, A. B. Two
Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different
patterns of infection in the mosquito, Aedes albopictus. PLoS One 2007, 2, e1168.
15. Pages, F.; Peyrefitte, C. N.; Mve, M. T.; Jarjaval, F.; Brisse, S.; Iteman, I.; Gravier, P.;
Tolou, H.; Nkoghe, D.; Grandadam, M. Aedes albopictus mosquito: the main vector of the
2007 Chikungunya outbreak in Gabon. PLoS One 2009, 4, e4691.
16. Gratz, N. G. Critical review of the vector status of Aedes albopictus. Med. Vet. Entomol.
2004, 18, 215-227.
17. Smith, C. E. The history of dengue in tropical Asia and its probable relationship to the
mosquito Aedes aegypti. J. Trop. Med. Hyg. 1956, 59, 243-251.
18. Gerardin, P.; Barau, G.; Michault, A.; Bintner, M.; Randrianaivo, H.; Choker, G.; Lenglet,
Y.; Touret, Y.; Bouveret, A.; Grivard, P.; Le Roux, K.; Blanc, S.; Schuffenecker, I.;
Couderc, T.; Arenzana-Seisdedos, F.; Lecuit, M.; Robillard, P. Y. Multidisciplinary
prospective study of mother-to-child chikungunya virus infections on the island of La
Reunion. PLoS Med 2008, 5, e60.
19. Ziegler, S. A.; Lu, L.; da Rosa, A. P.; Xiao, S. Y.; Tesh, R. B. An animal model for
studying the pathogenesis of chikungunya virus infection. Am. J. Trop. Med. Hyg. 2008, 79,
133-139.

48

20. Queyriaux, B.; Simon, F.; Grandadam, M.; Michel, R.; Tolou, H.; Boutin, J. P. Clinical
burden of chikungunya virus infection. Lancet Infect. Dis. 2008, 8, 2-3.
21. Santhosh, S. R.; Dash, P. K.; Parida, M. M.; Khan, M.; Tiwari, M.; Lakshmana Rao, P. V.
Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya
virus isolates. Virus Res. 2008, 135, 36-41.
22. Robin, S.; Ramful, D.; Le Seach, F.; Jaffar-Bandjee, M. C.; Rigou, G.; Alessandri, J. L.
Neurologic manifestations of pediatric chikungunya infection. J. Child. Neuro. 2008, 23,
1028-1035.
23. Chandak, N. H.; Kashyap, R. S.; Kabra, D.; Karandikar, P.; Saha, S. S.; Morey, S. H.;
Purohit, H. J.; Taori, G. M.; Daginawala, H. F. Neurological complications of Chikungunya
virus infection. Neurol. India 2009, 57, 177-180.
24. Pialoux, G.; Gauzere, B. A.; Jaureguiberry, S.; Strobel, M. Chikungunya, an epidemic
arbovirosis. Lancet Infect. Dis. 2007, 7, 319-327.
25. Mahesh, G.; Giridhar, A.; Shedbele, A.; Kumar, R.; Saikumar, S. J. A case of bilateral
presumed chikungunya neuroretinitis. Indian J. Ophthalmol. 2009, 57, 148-150.
26. Nair, A. G.; Biswas, J.; Bhende, M. P. A case of bilateral Chikungunya neuroretinitis.
J. Ophthalmic Inflammation Infect. 2012, 2, 39-40.
27. Couderc, T.; Gangneux, N.; Chretien, F.; Caro, V.; Le Luong, T.; Ducloux, B.; Tolou, H.;
Lecuit, M.; Grandadam, M. Chikungunya virus infection of corneal grafts. J. Infect. Dis.
2012, 206, 851-859.
28. Singh, S. K.; Unni, S. K. Chikungunya virus: host pathogen interaction. Rev. Med. Virol.
2011, 21, 78-88.

49

29. Grakoui, A.; Levis, R.; Raju, R.; Huang, H. V.; Rice, C. M. A Cis-Acting Mutation in the
Sindbis Virus Junction Region Which Affects Subgenomic Rna-Synthesis. J. Virol. 1989,
63, 5216-5227.
30. Sourisseau, M.; Schilte, C.; Casartelli, N.; Trouillet, C.; Guivel-Benhassine, F.; Rudnicka,
D.; Sol-Foulon, N.; Le Roux, K.; Prevost, M. C.; Fsihi, H.; Frenkiel, M. P.; Blanchet, F.;
Afonso, P. V.; Ceccaldi, P. E.; Ozden, S.; Gessain, A.; Schuffenecker, I.; Verhasselt, B.;
Zamborlini, A.; Saib, A.; Rey, F. A.; Arenzana-Seisdedos, F.; Despres, P.; Michault, A.;
Albert, M. L.; Schwartz, O. Characterization of reemerging chikungunya virus. PLoS
Pathog 2007, 3, e89.
31. Wintachai, P.; Wikan, N.; Kuadkitkan, A.; Jaimipuk, T.; Ubol, S.; Pulmanausahakul, R.;
Auewarakul, P.; Kasinrerk, W.; Weng, W. Y.; Panyasrivanit, M.; Paemanee, A.;
Kittisenachai, S.; Roytrakul, S.; Smith, D. R. Identification of prohibitin as a Chikungunya
virus receptor protein. J. Med. Virol. 2012, 84, 1757-1770.
32. Berger, K. H.; Yaffe, M. P. Prohibitin family members interact genetically with
mitochondrial inheritance components in Saccharomyces cerevisiae. Mol. Cell Biol. 1998,
18, 4043-4052.
33. Kolonin, M. G.; Saha, P. K.; Chan, L.; Pasqualini, R.; Arap, W. Reversal of obesity by
targeted ablation of adipose tissue. Nature med. 2004, 10, 625-632.
34. Kielian, M.; Rey, F. A. Virus membrane-fusion proteins: more than one way to make a
hairpin. Nature Rev.Microbiol. 2006, 4, 67-76.
35. Marsh, M.; Helenius, A. Virus entry: open sesame. Cell 2006, 124, 729-740.
36. Chatterjee, P. K.; Vashishtha, M.; Kielian, M. Biochemical consequences of a mutation that
controls the cholesterol dependence of Semliki Forest virus fusion. J. Virol. 2000, 74, 16231631.
50

37. Smit, J. M.; Bittman, R.; Wilschut, J. Low-pH-dependent fusion of Sindbis virus with
receptor-free cholesterol- and sphingolipid-containing liposomes. J. Virol. 1999, 73, 84768484.
38. Barton, D. J.; Sawicki, S. G.; Sawicki, D. L. Solubilization and immunoprecipitation of
alphavirus replication complexes. J. Virol. 1991, 65, 1496-1506.
39. Shirako, Y.; Strauss, J. H. Regulation of Sindbis virus RNA replication: uncleaved P123
and nsP4 function in minus-strand RNA synthesis, whereas cleaved products from P123 are
required for efficient plus-strand RNA synthesis. J. Virol.1994, 68, 1874-1885.
40. Schilte, C.; Couderc, T.; Chretien, F.; Sourisseau, M.; Gangneux, N.; Guivel-Benhassine,
F.; Kraxner, A.; Tschopp, J.; Higgs, S.; Michault, A.; Arenzana-Seisdedos, F.; Colonna, M.;
Peduto, L.; Schwartz, O.; Lecuit, M.; Albert, M. L. Type I IFN controls chikungunya virus
via its action on nonhematopoietic cells. J. Exp. Med. 2010, 207, 429-442.
41. Khan, A. H.; Morita, K.; Parquet Md Mdel, C.; Hasebe, F.; Mathenge, E. G.; Igarashi, A.
Complete nucleotide sequence of chikungunya virus and evidence for an internal
polyadenylation site. J. Gen. Virol. 2002, 83, 3075-3084.
42. Tang, B. L. The cell biology of Chikungunya virus infection. Cell. Microbiol. 2012, 14,
1354-1363.
43. Perera, R.; Owen, K. E.; Tellinghuisen, T. L.; Gorbalenya, A. E.; Kuhn, R. J. Alphavirus
nucleocapsid protein contains a putative coiled coil alpha-helix important for core assembly.
J. Virol. 2001, 75, 1-10.
44. Maek-a-nantawat, A. ; Silachamroon, U. Presence of autoimmune antibody in chikungunya
infection. Case Report Med. 2009, 2009, 840183, doi:10.1155/2009/840183.
45. Eckels, K. H.; Harrison, V. R.; Hetrick, F. M. Chikungunya virus vaccine prepared by
Tween-ether extraction. Appl. Microbiol. 1970, 19, 321-325.
51

46. Levitt, N. H.; Ramsburg, H. H.; Hasty, S. E.; Repik, P. M.; Cole, F. E.; Lupton, H. W.
Development of an Attenuated Strain of Chikungunya Virus for Use in Vaccine Production.
Vaccine 1986, 4, 157-162.
47. McClain, D. J.; Pittman, P. R.; Ramsburg, H. H.; Nelson, G. O.; Rossi, C. A.; Mangiafico,
J. A.; Schmaljohn, A. L.; Malinoski, F. J. Immunologic interference from sequential
administration of live attenuated alphavirus vaccines. J. Infect. Dis. 1998, 177, 634-641.
48. Edelman, R.; Tacket, C. O.; Wasserman, S. S.; Bodison, S. A.; Perry, J. G.; Mangiafico, J.
A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD218. Am. J. Trop. Med. Hyg. 2000, 62, 681-685.
49. Tiwari, M.; Parida, M.; Santhosh, S. R.; Khan, M.; Dash, P. K.; Rao, P. V. Assessment of
immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel
ECSA genotype of Chikungunya virus. Vaccine 2009, 27, 2513-2522.
50. Plante, K.; Wang, E. Y.; Partidos, C. D.; Weger, J.; Gorchakov, R.; Tsetsarkin, K.; Borland,
E. M.; Powers, A. M.; Seymour, R.; Stinchcomb, D. T.; Osorio, J. E.; Frolov, I.; Weaver, S.
C. Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host
Range

Alteration

Mechanism.

Plos

Pathogens

2011,

7,

e1002142

DOI:

10.1371/journal.ppat.1002142.
51. Velez, R. A.; de Matos, A. P. A.; Parreira, R.; Piedade, J.; Matos, B.; Correia, C.; Esteves,
A. Expression of Chikungunya virus-like particles. Microsc. Microanal. 2012, 18, 59-60.
52. Akahata, W.; Nabel, G. J. A Specific Domain of the Chikungunya Virus E2 Protein
Regulates Particle Formation in Human Cells: Implications for Alphavirus Vaccine Design.
J. .Virol. 2012, 86, 8879-8883.
53. Akahata, W.; Yang, Z. Y.; Andersen, H.; Sun, S.; Holdaway, H. A.; Kong, W. P.; Lewis, M.
G.; Higgs, S.; Rossmann, M. G.; Rao, S.; Nabel, G. J. A virus-like particle vaccine for
52

epidemic Chikungunya virus protects nonhuman primates against infection. Nature
Medicine 2010, 16, 334-338.
54. Solignat, M.; Gay, B.; Higgs, S.; Briant, L.; Devaux, C. Replication cycle of chikungunya: a
re-emerging arbovirus. Virology 2009, 393, 183-197.
55. Jones, P. H.; Maric, M.; Madison, M. N.; Maury, W.; Roller, R. J.; Okeoma, C. M. BST2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by
CHIKV non-structural protein 1 (nsP1). Virology 2013, 438, 37-49.
56. Jones, P. H.; Mehta, H. V.; Maric, M.; Roller, R. J.; Okeoma, C. M. Bone marrow stromal
cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo.
Retrovirology 2012, 9, 10-22.
57. Hardy, W. R.; Strauss, J. H. Processing the Nonstructural Polyproteins of Sindbis Virus Nonstructural Proteinase Is in the C-Terminal Half of Nsp2 and Functions Both in Cis and
in Trans. J. Virol. 1989, 63, 4653-4664.
58. Merits, A.; Vasiljeva, L.; Ahola, T.; Kaariainen, L.; Auvinen, P. Proteolytic processing of
Semliki Forest virus-specific non-structural polyprotein by nsP2 protease. J. Gen. Virol.
2001, 82, 765-773.
59. Strauss, E. G.; De Groot, R. J.; Levinson, R.; Strauss, J. H. Identification of the active site
residues in the nsP2 proteinase of Sindbis virus. Virology 1992, 191, 932-940.
60. Vasiljeva, L.; Valmu, L.; Kaariainen, L.; Merits, A. Site-specific protease activity of the
carboxyl-terminal domain of Semliki Forest virus replicase protein nsP2. J. Biol. Chem.
2001, 276, 30786-30793.
61. Gorbalenya, A. E.; Koonin, E. V. Helicases - Amino-Acid-Sequence Comparisons and
Structure-Function-Relationships. Curr. Opin. Struct. Biol. 1993, 3, 419-429.

53

62. Kim, K. H.; Rumenapf, T.; Strauss, E. G.; Strauss, J. H. Regulation of Semliki Forest virus
RNA replication: a model for the control of alphavirus pathogenesis in invertebrate hosts.
Virology 2004, 323, 153-163.
63. Vasiljeva, L.; Merits, A.; Golubtsov, A.; Sizemskaja, V.; Kaariainen, L.; Ahola, T.
Regulation of the sequential processing of Semliki Forest virus replicase polyprotein. J.
Biol. Chem. 2003, 278, 41636-41645.
64. Pastorino, B. A.; Peyrefitte, C. N.; Almeras, L.; Grandadam, M.; Rolland, D.; Tolou, H. J.;
Bessaud, M. Expression and biochemical characterization of nsP2 cysteine protease of
Chikungunya virus. Virus Res. 2008, 131, 293-298.
65. Karpe, Y. A.; Aher, P. P.; Lole, K. S. NTPase and 5 '-RNA Triphosphatase Activities of
Chikungunya

Virus

nsP2

Protein.

PLoS

One

2011,

6,

e22336,

DOI:

10.1371/journal.pone.0022336.
66. Domsalla, A.; Melzig, M. F. Occurrence and properties of proteases in plant latices. Planta
medica 2008, 74, 699-711.
67. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.;
Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235242.
68. Grudkowska, M.; Zagdanska, B. Multifunctional role of plant cysteine proteinases. Acta
Biochim. Pol. 2004, 51, 609-624.
69. Singh Kh, D.; Kirubakaran, P.; Nagarajan, S.; Sakkiah, S.; Muthusamy, K.; Velmurgan, D.;
Jeyakanthan, J. Homology modeling, molecular dynamics, e-pharmacophore mapping and
docking study of Chikungunya virus nsP2 protease. J. Mol. Model. 2012, 18, 39-51.

54

70. Russo, A. T.; Malmstrom, R. D.; White, M. A.; Watowich, S. J. Structural basis for
substrate specificity of alphavirus nsP2 proteases. J. Mol. Graphics Modell. 2010, 29, 4653.
71. Bassetto, M.; De Burghgraeve, T.; Delang, L.; Massarotti, A.; Coluccia, A.; Zonta, N.;
Gatti, V.; Colombano, G.; Sorba, G.; Silvestri, R.; Tron, G. C.; Neyts, J.; Leyssen, P.;
Brancale, A. Computer-aided identification, design and synthesis of a novel series of
compounds with selective antiviral activity against chikungunya virus. Antiviral Res. 2013,
98, 12-18.
72. Breakwell, L.; Dosenovic, P.; Karlsson Hedestam, G. B.; D'Amato, M.; Liljestrom, P.;
Fazakerley, J.; McInerney, G. M. Semliki Forest virus nonstructural protein 2 is involved in
suppression of the type I interferon response. J. Virol.2007, 81, 8677-8684.
73. Frolov, I.; Garmashova, N.; Atasheva, S.; Frolova, E. I. Random Insertion Mutagenesis of
Sindbis Virus Nonstructural Protein 2 and Selection of Variants Incapable of
Downregulating Cellular Transcription. J. Virol. 2009, 83, 9031-9044.
74. Bourai, M.; Lucas-Hourani, M.; Gad, H. H.; Drosten, C.; Jacob, Y.; Tafforeau, L.;
Cassonnet, P.; Jones, L. M.; Judith, D.; Couderc, T.; Lecuit, M.; Andre, P.; Kummerer, B.
M.; Lotteau, V.; Despres, P.; Tangy, F.; Vidalain, P. O. Mapping of Chikungunya virus
interactions with host proteins identified nsP2 as a highly connected viral component. J.
Virol. 2012, 86, 3121-3134.
75. De, I.; Fata-Hartley, C.; Sawicki, S. G.; Sawicki, D. L. Functional analysis of nsP3
phosphoprotein mutants of Sindbis virus. J. Virol. 2003, 77, 13106-13116.
76. Lastarza, M. W.; Grakoui, A.; Rice, C. M. Deletion and duplication mutations in the Cterminal nonconserved region of Sindbis virus nsP3: effects on phosphorylation and on
virus replication in vertebrate and invertebrate cells. Virology 1994, 202, 224-232.
55

77. Li, G. P.; La Starza, M. W.; Hardy, W. R.; Strauss, J. H.; Rice, C. M. Phosphorylation of
Sindbis virus nsP3 in vivo and in vitro. Virology 1990, 179, 416-427.
78. Vihinen, H.; Ahola, T.; Tuittila, M.; Merits, A.; Kaariainen, L. Elimination of
phosphorylation sites of Semliki Forest virus replicase protein nsP3. J. .Biol Chem. 2001,
276, 5745-5752.
79. Tuittila, M. T.; Santagati, M. G.; Roytta, M.; Maatta, J. A.; Hinkkanen, A. E. Replicase
complex genes of Semliki Forest virus confer lethal neurovirulence. J. Virol. 2000, 74,
4579-4589.
80. Malet, H.; Coutard, B.; Jamal, S.; Dutartre, H.; Papageorgiou, N.; Neuvonen, M.; Ahola, T.;
Forrester, N.; Gould, E. A.; Lafitte, D.; Ferron, F.; Lescar, J.; Gorbalenya, A. E.; de
Lamballerie, X.; Canard, B. The crystal structures of Chikungunya and Venezuelan equine
encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J.
Virol. 2009, 83, 6534-6545.
81. Neuvonen, M.; Ahola, T. Differential activities of cellular and viral macro domain proteins
in binding of ADP-ribose metabolites. J. Mol. Biol. 2009, 385, 212-225.
82. Lulla, A.; Lulla, V.; Merits, A. Macromolecular assembly-driven processing of the 2/3
cleavage site in the alphavirus replicase polyprotein. J. Virol. 2012, 86, 553-565.
83. Shin, G.; Yost, S. A.; Miller, M. T.; Elrod, E. J.; Grakoui, A.; Marcotrigiano, J. Structural
and functional insights into alphavirus polyprotein processing and pathogenesis. Proc. Natl.
Acad. Sci. U. S. A. 2012, 109, 16534-16539.
84. Vasiljeva, L.; Merits, A.; Golubtsov, A.; Sizemskaja, V.; Kaariainen, L.; Ahola, T.
Regulation of the sequential processing of Semliki Forest virus replicase polyprotein. J.
Biol. Chem. 2003, 278, 41636-41645.

56

85. Rungrotmongkol, T.; Nunthaboot, N.; Malaisree, M.; Kaiyawet, N.; Yotmanee, P.;
Meeprasert, A.; Hannongbua, S. Molecular insight into the specific binding of ADP-ribose
to the nsP3 macro domains of chikungunya and venezuelan equine encephalitis viruses:
Molecular dynamics simulations and free energy calculations. J. Mol. Graphics Modell.
2010, 29, 347-353.
86. Neuvonen, M.; Kazlauskas, A.; Martikainen, M.; Hinkkanen, A.; Ahola, T.; Saksela, K.
SH3 domain-mediated recruitment of host cell amphiphysins by alphavirus nsP3 promotes
viral RNA replication. PLoS Pathog. 2011, 7, e1002383.
87. Fros, J. J.; Domeradzka, N. E.; Baggen, J.; Geertsema, C.; Flipse, J.; Vlak, J. M.; Pijlman,
G. P. Chikungunya virus nsP3 blocks stress granule assembly by recruitment of G3BP into
cytoplasmic foci. J. Virol. 2012, 86, 10873-10879.
88. Parker, F.; Maurier, F.; Delumeau, I.; Duchesne, M.; Faucher, D.; Debussche, L.; Dugue,
A.; Schweighoffer, F.; Tocque, B. A Ras-GTPase-activating protein SH3-domain-binding
protein. Mol. Cell. Biol. 1996, 16, 2561-2569.
89. Anderson, P.; Kedersha, N. Stress granules. Curr. Biol. 2009, 19, R397-398.
90. Shirako, Y.; Strauss, E. G.; Strauss, J. H. Suppressor mutations that allow Sindbis virus
RNA polymerase to function with nonaromatic amino acids at the N-terminus: Evidence for
interaction between nsP1 and nsP4 in minus-strand RNA synthesis. Virology 2000, 276,
148-160.
91. Rathore, A. P.; Ng, M. L.; Vasudevan, S. G. Differential unfolded protein response during
Chikungunya and Sindbis virus infection: CHIKV nsP4 suppresses eIF2alpha
phosphorylation. Virol. J. 2013, 10, 36, DOI: 10.1186/1743-422X-10-36.
92. Tardif, K. D.; Waris, G.; Siddiqui, A. Hepatitis C virus, ER stress, and oxidative stress.
Trends Microbiol. 2005, 13, 159-163.
57

93. Salminen, A.; Wahlberg, J. M.; Lobigs, M.; Liljestrom, P.; Garoff, H. Membrane fusion
process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein
complex controls virus entry. J. Cell Biol. 1992, 116, 349-357.
94. Li, L.; Jose, J.; Xiang, Y.; Kuhn, R. J.; Rossmann, M. G. Structural changes of envelope
proteins during alphavirus fusion. Nature 2010, 468, 705-708.
95. Voss, J. E.; Vaney, M. C.; Duquerroy, S.; Vonrhein, C.; Girard-Blanc, C.; Crublet, E.;
Thompson, A.; Bricogne, G.; Rey, F. A. Glycoprotein organization of Chikungunya virus
particles revealed by X-ray crystallography. Nature 2010, 468, 709-712.
96. Kuo, S. C.; Chen, Y. J.; Wang, Y. M.; Tsui, P. Y.; Kuo, M. D.; Wu, T. Y.; Lo, S. J. Cellbased analysis of Chikungunya virus E1 protein in membrane fusion. J. Biomed. Sci. 2012,
19, 44, DOI: 10.1186/1423-0127-19-44.
97. Kielian, M.; Rey, F. A. Virus membrane-fusion proteins: more than one way to make a
hairpin. Nat. Rev. Microbiol. 2006, 4, 67-76.
98. Weissenhorn, W.; Hinz, A.; Gaudin, Y. Virus membrane fusion. FEBS Lett. 2007, 581,
2150-2155.
99. Mohanram, H.; Nip, A.; Domadia, P. N.; Bhunia, A.; Bhattacharjya, S. NMR structure,
localization, and vesicle fusion of chikungunya virus fusion peptide. Biochemistry 2012, 51,
7863-7872.
100.Ozden, S.; Lucas-Hourani, M.; Ceccaldi, P. E.; Basak, A.; Valentine, M.; Benjannet, S.;
Hamelin, J.; Jacob, Y.; Mamchaoui, K.; Mouly, V.; Despres, P.; Gessain, A.; ButlerBrowne, G.; Chretien, M.; Tangy, F.; Vidalain, P. O.; Seidah, N. G. Inhibition of
Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment
of the maturation of the E2 surface glycoprotein. J. Biol. Chem. 2008, 283, 21899-21908.

58

101.Lobigs, M.; Zhao, H. X.; Garoff, H. Function of Semliki Forest virus E3 peptide in virus
assembly: replacement of E3 with an artificial signal peptide abolishes spike
heterodimerization and surface expression of E1. J. Virol. 1990, 64, 4346-4355.
102.Meyer, W. J.; Johnston, R. E. Structural Rearrangement of Infecting Sindbis Virions at the
Cell-Surface - Mapping of Newly Accessible Epitopes. J. Virol. 1993, 67, 5117-5125.
103.Meyer, W. J.; Gidwitz, S.; Ayers, V. K.; Schoepp, R. J.; Johnston, R. E. Conformational
alteration of Sindbis virion glycoproteins induced by heat, reducing agents, or low pH. J.
Virol. 1992, 66, 3504-3513.
104.Flynn, D. C.; Meyer, W. J.; Mackenzie, J. M., Jr.; Johnston, R. E. A conformational change
in Sindbis virus glycoproteins E1 and E2 is detected at the plasma membrane as a
consequence of early virus-cell interaction. J. Virol. 1990, 64, 3643-3653.
105.Rashad, A. A.; Keller, P. A. Structure Based Design towards the Identification of Novel
Binding Sites and Inhibitors for the Chikungunya Virus Envelope Proteins. J. Mol.
Graphics Modell. 2013, 44, 241-252.
106.de Lamballerie, X.; Ninove, L.; Charrel, R. N. Antiviral treatment of chikungunya virus
infection. Infec.t Disord. Drug Targets 2009, 9, 101-104.
107.Couderc, T.; Chretien, F.; Schilte, C.; Disson, O.; Brigitte, M.; Guivel-Benhassine, F.;
Touret, Y.; Barau, G.; Cayet, N.; Schuffenecker, I.; Despres, P.; Arenzana-Seisdedos, F.;
Michault, A.; Albert, M. L.; Lecuit, M. A mouse model for Chikungunya: young age and
inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008,
4, e29.
108.Yeo, L. S.; Chu, J. J. H. Recent developments and challenges in mouse models of
Chikungunya virus infection. Future Virol. 2013, 8, 423-426.

59

109.Inglot, A. D. Comparison of the Antiviral Activity in vitro of some Non-steroidal Antiinflammatory Drugs. J. Gen. Virol. 1969, 4, 203-204.
110.Shimizu, Y.; Yamamoto, S.; Homma, M.; Ishida, N. Effect of chloroquine on the growth of
animal viruses. Arch. Gesamte Virusforsch. 1972, 36, 93-104.
111.Coombs, K.; Mann, E.; Edwards, J.; Brown, D. T. Effects of chloroquine and cytochalasin
B on the infection of cells by Sindbis virus and vesicular stomatitis virus. J. Virol. 1981, 37,
1060-1065.
112.Helenius, A.; Marsh, M.; White, J. Inhibition of Semliki forest virus penetration by
lysosomotropic weak bases. J. Gen. Virol. 1982, 58, 47-61.
113.Cassell, S.; Edwards, J.; Brown, D. T. Effects of lysosomotropic weak bases on infection of
BHK-21 cells by Sindbis virus. J. Virol. 1984, 52, 857-864.
114.Maheshwari, R. K.; Srikantan, V.; Bhartiya, D. Chloroquine enhances replication of Semliki
Forest virus and encephalomyocarditis virus in mice. J. Virol. 1991, 65, 992-995.
115.Brighton, S. W. Chloroquine phosphate treatment of chronic Chikungunya arthritis. An
open pilot study. S. Afr. Med. J. 1984, 66, 217-218.
116.Leyssen, P.; De Clercq, E.; Neyts, J. The anti-yellow fever virus activity of ribavirin is
independent of error-prone replication. Mol. Pharmacol. 2006, 69, 1461-1467.
117.Briolant, S.; Garin, D.; Scaramozzino, N.; Jouan, A.; Crance, J. M. In vitro inhibition of
Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic
effect of interferon-alpha and ribavirin combination. Antiviral Research 2004, 61, 111-117.
118.Rada, B.; Dragun, M. Antiviral action and selectivity of 6-azauridine. Ann. N. Y. Acad. Sci.
1977, 284, 410-417.
119.Crutcher, W. A.; Moschella, S. L. Double-blind controlled crossover high-dose study of
Azaribine in psoriasis. Br. J. Dermatol. 1975, 92, 199-205.
60

120.Panisheva, E. K. F., A. N.; Nikolaeva, I. S.; Galenko-Yaroshevskii, P. A.; Bartashevich, V.
V.; Cherkasova, A. A.; Linchenko, S. N.; Egik'yan, A. L.; Golovanova, E. A.; Pushkina, T.
V. . Synthesis and biological activity of substituted 5-hydroxy-6-bromoindoles. Khim.Farm. Zh. 1988, 22 565-569.
121.Boriskin, Y. S.; Leneva, I. A.; Pecheur, E. I.; Polyak, S. J. Arbidol: A broad-spectrum
antiviral compound that blocks viral fusion. Curr. Med. Chem. 2008, 15, 997-1005.
122.Villalain, J. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid
model membranes. J. Phys. Chem. B 2010, 114, 8544-8554.
123.Leneva, I. A.; Russell, R. J.; Boriskin, Y. S.; Hay, A. J. Characteristics of arbidol-resistant
mutants of influenza virus: Implications for the mechanism of anti-influenza action of
arbidol. Antiviral Res. 2009, 81, 132-140.
124.Pecheur, E. I.; Lavillette, D.; Alcaras, F.; Molle, J.; Boriskin, Y. S.; Roberts, M.; Cosset, F.
L.; Polyak, S. J. Biochemical mechanism of hepatitis C virus inhibition by the broadspectrum antiviral arbidol. Biochemistry 2007, 46, 6050-6059.
125.Delogu, I.; Pastorino, B.; Baronti, C.; Nougairede, A.; Bonnet, E.; de Lamballerie, X. In
vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected
resistant mutant. Antiviral Res. 2011, 90, 99-107.
126.Bentley, R. Mycophenolic Acid: a one hundred year odyssey from antibiotic to
immunosuppressant. Chem. Rev. 2000, 100, 3801-3826.
127.Chen, L.; Pankiewicz, K. W. Recent development of IMP dehydrogenase inhibitors for the
treatment of cancer. Curr. Opin. Drug Discov. Devel. 2007, 10, 403-412.
128.Ratcliffe, A. J. Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of
autoimmune diseases. Cur.r Opin. Drug Discov. Devel. 2006, 9, 595-605.

61

129.Khan, M.; Dhanwani, R.; Patro, I. K.; Rao, P. V. L.; Parida, M. M. Cellular IMPDH enzyme
activity is a potential target for the inhibition of Chikungunya virus replication and virus
induced apoptosis in cultured mammalian cells. Antiviral Res. 2011, 89, 1-8.
130.Sweeney, M. J.; Hoffman, D. H.; Esterman, M. A. Metabolism and biochemistry of
mycophenolic acid. Cancer Res. 1972, 32, 1803-1809.
131.Bopp, R. J.; Schirmer, R. E.; Meyers, D. B. Determination of mycophenolic acid and its
glucuronide metabolite in plasma. J. Pharm. Sci. 1972, 61, 1750-1753.
132.Fan, D.; Ju, H.; Shao-Yong, Y.; Xia, C.; Da-Cai, Z.; Ye-Na, T. Trigonostemon tuberculatus
(Euphorbiaceae), a peculiar new species from Yunnan Province, China. Kew Bull. 2010, 65,
111-113.
133.Lin, B. D.; Han, M. L.; Ji, Y. C.; Chen, H. D.; Yang, S. P.; Zhang, S.; Geng, M. Y.; Yue, J.
M. Trigoxyphins A-G: diterpenes from Trigonostemon xyphophylloides. J. Nat. Prod.
2010, 73, 1301-1305.
134.Dong, S. H.; Zhang, C. R.; Xu, C. H.; Ding, J.; Yue, J. M. Daphnane-type diterpenoids from
Trigonostemon howii. J. Nat. Prod. 2011, 74, 1255-1261.
135.Zhang, L.; Luo, R. H.; Wang, F.; Jiang, M. Y.; Dong, Z. J.; Yang, L. M.; Zheng, Y. T.; Liu,
J. K. Highly functionalized daphnane diterpenoids from Trigonostemon thyrsoideum. Org.
Lett. 2010, 12, 152-155.
136.Zhang, L.; Luo, R. H.; Wang, F.; Dong, Z. J.; Yang, L. M.; Zheng, Y. T.; Liu, J. K.
Daphnane diterpenoids isolated from Trigonostemon thyrsoideum as HIV-1 antivirals.
Phytochemistry 2010, 71, 1879-1883.
137.Allard, P. M.; Martin, M. T.; Tran Huu Dau, M. E.; Leyssen, P.; Gueritte, F.; Litaudon, M.
Trigocherrin A, the First Natural Chlorinated Daphnane Diterpene Orthoester from
Trigonostemon cherrieri. Org. Let.t 2012, 14, 342-345.
62

138.Allard, P. M.; Leyssen, P.; Martin, M. T.; Bourjot, M.; Dumontet, V.; Eydoux, C.;
Guillemot, J. C.; Canard, B.; Poullain, C.; Gueritte, F.; Litaudon, M. Antiviral chlorinated
daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri.
Phytochemistry 2012, 84, 160-168.
139.Bourjot, M.; Delang, L.; Nguyen, V. H.; Neyts, J.; Gueritte, F.; Leyssen, P.; Litaudon, M.
Prostratin and 12-O-Tetradecanoylphorbol 13-Acetate Are Potent and Selective Inhibitors
of Chikungunya Virus Replication. J. Nat. Prod. 2012, 75, 2183-2187.
140.Hezareh, M. Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug
News Perspect. 2005, 18, 496-500.
141.Chowdhury, M. I. H.; Koyanagi, Y.; Kobayashi, S.; Hamamoto, Y.; Yoshiyama, H.;
Yoshida, T.; Yamamoto, N. The Phorbol Ester Tpa Strongly Inhibits Hiv-1-Induced
Syncytia Formation but Enhances Virus Production - Possible Involvement of Protein
Kinase-C Pathway. Virology 1990, 176, 126-132.
142.Voet, D. V., J. G. In In Biochimie; de Boeck, Ed., Université: Bruxelles: 2005; p 712.
143.Szallasi, Z.; Krsmanovic, L.; Blumberg, P. M. Nonpromoting 12-deoxyphorbol 13-esters
inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin.
Cancer Res. 1993, 53, 2507-2512.
144.Bourjot, M.; Leyssen, P.; Eydoux, C.; Guillemot, J. C.; Canard, B.; Rasoanaivo, P.;
Gueritte, F.; Litaudon, M. Chemical constituents of Anacolosa pervilleana and their
antiviral activities. Fitoterapia 2012, 83, 1076-1080.
145.Takeda, S.; Yajima, N.; Kitazato, K.; Unemi, N. Antitumor activities of harringtonine and
homoharringtonine, cephalotaxus alkaloids which are active principles from plant by
intraperitoneal and oral administration. J. Pharmacobio-Dyn. 1982, 5, 841-847.

63

146.Kaur, P.; Thiruchelvan, M.; Lee, R. C.; Chen, H.; Chen, K. C.; Ng, M. L.; Chu, J. J.
Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that
suppresses viral protein expression. Antimicrob. Agents Chemother. 2013, 57, 155-167.
147.D'Hooghe, M.; Mollet, K.; De Vreese, R.; Jonckers, T. H.; Dams, G.; De Kimpe, N. Design,
synthesis, and antiviral evaluation of purine-beta-lactam and purine-aminopropanol hybrids.
J. Med. Chem. 2012, 55, 5637-5641.
148.Field, A. K.; Tytell, A. A.; Lampson, G. P.; Hilleman, M. R. Inducers of interferon and host
resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl. Acad. Sci. U.
S. A. 1967, 58, 1004-1010.
149.Djeu, J. Y.; Heinbaugh, J. A.; Holden, H. T.; Herberman, R. B. Role of macrophages in the
augementation of mouse natural killer cell activity by poly I:C and interferon. J. Immunol.
1979, 122, 182-1588.
150.Guillot, L.; Le Goffic, R.; Bloch, S.; Escriou, N.; Akira, S.; Chignard, M.; Si-Tahar, M.
Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to
double-stranded RNA and influenza A virus. J. Biol. Chem. 2005, 280, 5571-5580.
151.Li, Y. G.; Siripanyaphinyo, U.; Tumkosit, U.; Noranate, N.; A, A. N.; Pan, Y.; Kameoka,
M.; Kurosu, T.; Ikuta, K.; Takeda, N.; Anantapreecha, S. Poly (I:C), an agonist of toll-like
receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. Virology
journal 2012, 9, 114, DOI: 10.1186/1743-422X-9-114.
152.Dash, P. K.; Tiwari, M.; Santhosh, S. R.; Parida, M.; Rao, P. V. L. RNA interference
mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem.
Biophys. Res. Commun. 2008, 376, 718-722.

64

153.Lam, S.; Chen, K. C.; Ng, M. M.; Chu, J. J. Expression of plasmid-based shRNA against
the E1 and nsP1 genes effectively silenced Chikungunya virus replication. PLoS One 2012,
7, e46396.

65

Table of Contents Graphic

66

